Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated with ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

The trial included 1,407 randomised adults with obesity. All treatment ... 1,407 adults with BMI ≥30 kg/m 2 and without ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

Semaglutide (known by its brandname Ozempic) has gained widespread attention for its weight loss benefits, but is officially ...

This has important implications, since the prevalence of obesity in people with type 1 diabetes ... without high blood sugars or acidosis that occurred while participants were using semaglutide.